MabVax Therapeutics Holdings, Inc.

Equities

MBVXQ

US55414P7024

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets			5-day change	1st Jan Change
- ^USD	-.--%		+10.05%	+182.21%

2020	MabVax Therapeutics Holdings, Inc. Went Out of Business	CI
2020	Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc.	CI

MabVax Therapeutics Holdings, Inc. Therapeutics to Present Positive Development Study Results Enabling Manufacturing of Two Radionuclide Products for Phase 1 Clinical Trials at the 2017 AAPS Annual Meeting

November 13, 2017 at 06:00 pm IST

MabVax Therapeutics Holdings, Inc. announced the results from the manufacturing process development and characterization of the Company's immunoPET imaging agent (MVT-2163) and radioimmunotherapy agent (MVT-1075) which are being evaluated in advanced pancreatic cancer and other CA19-9 positive cancers. The results will be presented in a poster presentation at the American Association of Pharmaceutical Scientists to be held in San Diego, CA, November 12 - 15, 2017.

Latest news about MabVax Therapeutics Holdings, Inc.

MabVax Therapeutics Holdings, Inc. Went Out of Business	20/20/20	CI
Second Amended Liquidation Plan & Disclosure Statment Approved for MabVax Therapeutics Holdings, Inc.	05/20/05	CI
Second Amended Liquidation Plan and Disclosure Statement Conditionally Approved for MabVax Therapeutics Holdings, Inc.	10/20/10	CI
Second Amended Combined Joint Liquidation Plan and Disclosure Statement Filed by MabVax Therapeutics Holdings, Inc.	08/20/08	CI
First Amended Combined Joint Liquidation Plan Filed by MabVax Therapeutics Holdings, Inc.	16/19/16	CI
Joint Liquidation Plan and Disclosure Statement Filed by MabVax Therapeutics Holdings, Inc.	27/19/27	CI
Second Motion for Exclusivity Period Extension Approved For MabVax Therapeutics Holdings, Inc.	06/19/06	CI
Motion for Exclusivity Period Extension Approved For MabVax Therapeutics Holdings, Inc.	29/19/29	CI
First Motion for Exclusivity Period Extension Filed by MabVax Therapeutics Holdings, Inc.	10/19/10	CI
Motion for Asset Sale Approved for MabVax Therapeutics Holdings, Inc.	26/19/26	CI
Bankruptcy Judge Changed for MabVax Therapeutics Holdings, Inc.	12/19/12	CI
BioNTech Research and Development, Inc. completed the acquisition of substantially all assets from MabVax Therapeutics Holdings, Inc..	08/19/08	CI
Motion for Asset Sale Approved for MabVax Therapeutics Holdings, Inc.	07/19/07	CI
Notice of Successful Bidder and Back-Up Bidder Filed by MabVax Therapeutics Holdings, Inc.	02/19/02	CI
Oncotelic Inc. cancelled the acquisition of MabVax Therapeutics Holdings, Inc. in a reverse merger transaction.	17/19/17	CI
Bidding Procedure Approved for MabVax Therapeutics Holdings, Inc.	08/19/08	CI
Final DIP Financing Approved for MabVax Therapeutics Holdings, Inc.	04/19/04	CI
Interim DIP Financing Approved for MabVax Therapeutics Holdings, Inc.	22/19/22	CI
Motion for Joint Administration Approved for MabVax Therapeutics Holdings, Inc.	22/19/22	CI
MabVax Therapeutics Holdings, Inc. Filed for Bankruptcy	21/19/21	CI
Motion for Joint Administration Filed by MabVax Therapeutics Holdings, Inc.	21/19/21	CI
Motion for Sale of Substantially All Assets Filed by MabVax Therapeutics Holdings, Inc.	21/19/21	CI
BioNTech Research and Development, Inc. agreed to acquire substantially all assets from MabVax Therapeutics Holdings, Inc. for $2.3 million.	21/19/21	CI
Oncotelic Inc. signed a non-binding letter of intent to acquire MabVax Therapeutics Holdings, Inc. in a reverse merger transaction.	04/19/04	CI
MabVax Therapeutics Engages Objective Capital as Advisor for Exploring Asset Sales	13/18/13	CI

Chart MabVax Therapeutics Holdings, Inc.

Duration

Period

Chart MabVax Therapeutics Holdings, Inc.

More charts

Company Profile

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform. The Company is focused on the translation into clinical development of products to address the medical needs in the treatment of cancer and pancreatitis. The Company discovered a pipeline of human monoclonal antibody product candidates based on the immune responses generated by patients. The Company's product pipeline includes ImmunoPET Imaging (MVT-2163) and Radioimmunotherapy (MVT-1075). MVT-2163 is an imaging agent for pancreatic cancer. MVT-1075 is a radioimmunotherapy for pancreatic cancer.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MABVAX THERAPEUTICS HOLDINGS, INC.	+182.21%	213K
VERTEX PHARMACEUTICALS INCORPORATED	+12.30%	116B
REGENERON PHARMACEUTICALS, INC.	+12.15%	106B
BIONTECH SE	-8.14%	23.89B
ARGENX SE	-1.69%	21.58B
GENMAB A/S	-10.60%	18.96B
WUXI APPTEC CO., LTD.	-41.25%	16.96B
BEIGENE, LTD.	-15.33%	16.33B
NEUROCRINE BIOSCIENCES, INC.	+5.80%	14.14B
SAREPTA THERAPEUTICS, INC.	+28.03%	12.02B

Bio Therapeutic Drugs